Luveltamab tazevibulin,Pegfilgrastim
Sutro Biopharma,Amgen
['pivotal study', 'pivot,io,i', 'ovarian', '$stro', 'sutro']
$stro sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer. the phase 2/3 pivotal study of luvelta for patients with platinum-resistant ovarian canc... 
Financial news recaps and ticker rating curated by AI language models. Fine tuned on analyst articles and return alpha. More exposure to lesser known companies.